Cryoport (CYRX) Competitors

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Do analysts prefer AUPH or CYRX?

Aurinia Pharmaceuticals currently has a consensus price target of $11.50, suggesting a potential upside of 41.10%. Cryoport has a consensus price target of $11.00, suggesting a potential upside of 62.24%. Given Cryoport's higher possible upside, analysts plainly believe Cryoport is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cryoport	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Does the media refer more to AUPH or CYRX?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 7 articles in the media. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Cryoport's score of 0.86 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cryoport	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of AUPH or CYRX?

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.9% of Cryoport shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 10.0% of Cryoport shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Which has more volatility and risk, AUPH or CYRX?

Aurinia Pharmaceuticals has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Does the MarketBeat Community favor AUPH or CYRX?

Aurinia Pharmaceuticals received 325 more outperform votes than Cryoport when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 65.80% of users gave Cryoport an outperform vote.

Company	Underperform	Outperform
Aurinia Pharmaceuticals	Outperform Votes 577 73.41%	Underperform Votes 209 26.59%
Cryoport	Outperform Votes 252 65.80%	Underperform Votes 131 34.20%

Which has preferable earnings & valuation, AUPH or CYRX?

Aurinia Pharmaceuticals has higher revenue and earnings than Cryoport. Cryoport is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$247.30M	4.45	-$78.02M	$0.28	29.11
Cryoport	$232.13M	1.46	-$99.59M	-$2.34	-2.90

Is AUPH or CYRX more profitable?

Aurinia Pharmaceuticals has a net margin of -10.23% compared to Cryoport's net margin of -70.08%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Cryoport's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	-10.23%	-4.41%	-3.07%
Cryoport	-70.08%	-13.35%	-6.43%

Summary

Aurinia Pharmaceuticals beats Cryoport on 12 of the 17 factors compared between the two stocks.